Product Pipeline Pipeline

Our Pipeline

Progenics has a pipeline that includes products in pre-clinical through late-stage development. We are focused on critical unmet diagnostic and therapeutic needs of prostate cancer patients.

PSMA Targeted Oncology

  • PSMA Targeted Imaging Compound (1404)

    Prostate / Imaging

    1404 is a targeted small molecule imaging agent candidate that visualizes prostate cancer by targeting PSMA.  The expression of PSMA by tumor cells offers the opportunity to “visualize cancer” by imaging 1404’s radioactive payload.  1404 is aimed at improving detection and staging, more precise biopsies, and a targeted treatment plan that utilizes active surveillance as a disease management tool. MORE>

  • PSMA ADC Therapeutic

    Prostate / Therapeutic

    PSMA ADC is an Antibody-Drug Conjugate candidate that targets prostate specific membrane antigen, a protein expressed on the surface of almost all prostate  cancer tumor cells and in the neovasculature that supplies many other tumors.  This targeted therapeutic is designed to seek out and kill cancer cells with minimal damage to surrounding healthy tissue.  MORE>

  • PSMA Targeting Small Molecule Therapeutic (1095)

    Prostate / Therapeutic

    1095 is a PSMA-targeted small molecule radiopharmaceutical candidate for the treatment of metastatic prostate cancer.  1095 is designed to deliver lethal doses of radiation to prostate cancer cells while causing minimal damage to healthy surrounding tissue.  Memorial Sloan Kettering Cancer Center, a member of the Prostate Cancer Clinical Trials Consortium, has been designated as the principal site for a phase 1 study. MORE>


  • Azedra

    SPA Pheochromocytoma / Neuroblastoma / Neuroendocrine

    Azedra is a late-stage ultra-orphan candidate being developed for the treatment of malignant pheochromocytoma and paraganglioma.  Clinical testing is being conducted under a Special Protocol Assessment which may accelerate FDA review and marketing approval decisions.

  • Kinase

    Solid Tumors

    Progenics’ kinase program seeks to intercept signals that cancer cells rely on to grow and divide.  We have discovered novel small molecules that are undergoing lead optimization.

Oncology Supportive Care

  • Relistor SC (AI)

    OIC Advanced Illness

    RELISTOR subcutaneous injection, a small-molecule mu-opioid receptor antagonist, is approved in the United States for the treatment of opioid induced constipation in patients with advanced illness. Progenics has licensed Relistor to Salix Pharmaceuticals in markets worldwide.

  • Relistor SC (CP)

    OIC Chronic Pain

    Results of a phase 3 trial of Relistor SC in chronic pain patients showed statistically significant improvements over placebo in rescue free bowel movements (RFBMs) within 4 hours of injection, time to first RFBM, and increase in weekly RFBMs from baseline.  Salix's supplemental New Drug Application (sNDA) for subcutaneous Relistor for opioid-induced constipation in patients with chronic non-cancer pain has been assigned a user fee (PDUFA) goal date of September 29, 2014.

  • Relistor SC (AI-Japan)

    OIC Advanced Illness
  • Relistor Oral

    OIC Chronic Pain

    A completed phase 3 trial of oral Relistor has shown a highly significant improvement in RFBM within 4 hours of dosing and in laxation response over 4 weeks.  Salix and Progenics are working with regulatory agencies to define a path for marketing approval of this formulation.

Partnered Programs

  • PRO 140

    HIV Viral Entry Inhibitor

    PRO 140 is a humanized anti-CCR5 monoclonal antibody created at Progenics and now developed by CytoDyn Inc.  PRO 140 is in Phase 2 testing as a treatment for human immunodeficiency virus (HIV) infection.  MORE>

  • PRO 391

    Antibodies Targeting C.diff Toxins

    C. difficile is a pair of humanized antibodies that neutralize the disease-causing toxins of Clostridium difficile.  PRO 391 provides a non-antibiotic approach to managing this important and life-threatening disease.  MORE>